Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

Data Indicate Dual Modes of Action and Synergy with Chemotherapy

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy for breast cancer. The studies were conducted at Imperial College London and presented at the International Conference titled "Realizing the Commercial Potential of Therapeutic Antibodies," held in London, UK.

"We are delighted with these results which demonstrate the substantial anti-cancer effect of Angiolix, which we feel is comparable to Avastin yet achieved through a different and potentially complementary mechanism of action," stated Jeffrey B. Davis, President & CEO. "As stated previously, Access is actively seeking potential partners for the further clinical development of Angiolix."

"Angiolix is highly tumor specific," continued Agamemnon Epenetos, Chief Scientific Officer, Europe, "because the target lactadherin is primarily found in tumors and not in normal tissues. Other targets, such as VEGF, are present in many normal tissues; the blocking of VEGF may contribute to side effects such as high blood pressure and bleeding episodes, for example. Angiolix appears to be a more tumor selective anti-angiogenesis monoclonal antibody, with the benefit of having anti-proliferative activity."

Access is continuing to conduct pre-clinical studies at Imperial College London to more fully define the safety and efficacy profile of Angiolix.

About Angiolix:

Angiolix is a novel humanized monoclonal antibody which has considerable potential for the treatmen
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... YORK , Sept. 3, 2015 This ... used to save millions of lives across globe. This ... Kingdom of Saudi Arabia . Stakeholders ... material suppliers, government agencies and regulatory bodies. The ... studied from two perspectives: by products and by end ...
(Date:9/3/2015)... Calif. , Sept. 3, 2015 Nevro ... company that is providing innovative evidence-based solutions for the ... will be presenting at the Morgan Stanley Global Healthcare ... City.  Nevro management is scheduled to ... accessible via a live audio webcast, accessible in the ...
(Date:9/3/2015)... 2015  Ascendis Pharma A/S (Nasdaq: ... that applies its innovative TransCon technology to ... plans to present at several upcoming investor ... in BostonDate: , Thursday, September 10, 2015 Time: ... Merrill Lynch Global Healthcare Conference in LondonDate: ...
Breaking Medicine Technology:Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... LOS ANGELES , July 13 Medical Tactile, Inc. ... Medical Technologies, Inc., based in Victoria , Canada , has ... the exclusive Sales & Marketing rights for SureTouch™ , the non-invasive ... , , , ...
... New England Biolabs (NEB) has expanded its line ... Quick DNA Sample Prep Reagent Set 2 and Master Mix ... GS FLX Titanium™ and GS Junior™ instruments. These new products ... library preparation. The Master Mix Set further streamlines the workflow, ...
Cached Medicine Technology:Partnership Brings Breast Image Documentation Technology to Women Around the World 2New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms 2
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way ... , The patent-pending K Med Cups provide a quick and simple way to brew a ... cold, flu or cough. As a result, they enhance comfort and health. The invention features ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... 04, 2015 , ... Compliance officers deal with many high-risk ... physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices for Your ... (AIS), will detail which deals are attracting the most government scrutiny and what ...
(Date:9/4/2015)... ... September 04, 2015 , ... Friday night, Chicago lovebirds Jenny ... Rescue’s A Night of Hope event supporting families affected by autism, raising nearly $250,000. ... Joe Salas, joined together at the Oscar Swan Inn to support the cause. ...
(Date:9/3/2015)... ... September 03, 2015 , ... TransPack Toon gives users a set of 90 ... and framing transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, ... , TransPack Toon features 90 cartoon transitions from 30 unique styles. Editors can ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... to a couple of pegs when it comes to alcohol ... are capable of scaling down// the risks of a brain ... Indraprastha Apollo Hospital’s senior consultant Harsh Rastogi. ,"Drinking ... the more alcohol one consumes, the greater the risk of ...
... day by day and the mortality rate is also directly proportional ... the increasing number of AIDS/HIV patients// United Nations Development Program HIV/AIDS ... was started under the Global Fund for AIDS in Liberia. ... raise in the number of people affected by AIDS/HIV in the ...
... the US chief of AIDS research has revealed that the ... he is convinced that there is a lack of incentive ... of Health’s AIDS Research Chief made this announcement at an ... fetch profits, if the vaccine really works. ,Strong ...
... A research was conducted by the American Researchers Richard Ivry ... He said that left side of the brain // can ... same colour. This is due to the fact that the ... ,Researchers to study this feature of the brain ...
... genes such as microRNAs (miRNAs) belong to the newly ... of North Carolina have discovered two genes // belonging ... attributed to the proper development of muscles in the ... (1993) in the genome of the worms. The genes ...
... in United Kingdom which allows prescription of nicotine patches ... women as the risk associated with smoking is higher ... earlier the sale of nicotine patches was not allowed ... with chronic diseases such as heart, liver and kidney ...
Cached Medicine News:Health News:Colour Identification Lies Wholly On the Left Hemisphere of the Brain. 2Health News:Genetic mystery behind muscle development unraveled. 2
The ultra micro tip for the new Eppendorf 2000/2100 series ultra micro pipettors provides accurate drawing and dispensing everytime....
... Sterilized Diamond Tips are available as ... Tips are irradiated by gamma-rays for more ... certificate of sterilization, specifying the date of ... usepractical, no need to autoclave. SterilPack Diamond ...
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: